

‘What’s in the COVID mRNA vaccine?’

Prof. Stephen KENT

Dept. of Microbiology and Immunology
Peter Doherty Institute
University of Melbourne, Australia



Prof. S. KENT

[Link](#) to Kent Lab

Date: May 13 (Mon) 2024

Time: 4 pm – 5 pm

Venue: Meeting Room #1, 2nd FL, IFRcC Building

Chair: Kiyoshi Takeda (Director of IFRcC)

*A credit seminar for the Graduate School of Medicine and the Graduate School of Frontier Biosciences

A vaccine against HIV and improved Influenza vaccines are urgently needed. The Kent lab is working towards these goals. Our dedicated staff and students drive innovation and new thinking in ways to tackle the HIV/AIDS epidemic. Prof Kent was awarded the Peter Doherty Award for Outstanding PhD Supervision which reflects the quality of our work and PhD students in this area.

The Kent lab began working on the pandemic coronavirus research since early 2020. We have taken our knowledge on immunity to HIV and Influenza and applying it to develop antibody treatments and vaccines for SARS-CoV2, the cause of the COVID-19 illness. We have recruited blood and other samples from people who have recovered from COVID-19 to understand how their antibodies work to control COVID-19. One of our team has generated monoclonal antibodies as a potential therapy or prophylaxis for COVID-19. Our work on generating monoclonal antibodies against influenza provides a sound basis for this.